{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:03:15Z","timestamp":1791198195858,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecular evidence of persistent disease has been observed in 20-25% of IM treated patients. The existence of second generation TK inhibitors, which are effective in patients with IM resistance, makes identification of predictors of resistance to IM an important goal in CML. In this study, we have identified a group of 19 miRNAs that may predict clinical resistance to IM in patients with newly diagnosed CML.<\/jats:p>","DOI":"10.1186\/1476-4598-8-69","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T18:14:08Z","timestamp":1251828848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations"],"prefix":"10.1186","volume":"8","author":[{"given":"Edurne","family":"San Jos\u00e9-En\u00e9riz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Rom\u00e1n-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jim\u00e9nez-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Garate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Cordeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Vilas-Zornoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Jos\u00e9 Calasanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Pr\u00f3sper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Agirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,1]]},"reference":[{"key":"454_CR1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF: Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncology. 2007, 8: 1018-29. 10.1016\/S1470-2045(07)70342-X","journal-title":"Lancet Oncology"},{"key":"454_CR2","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine. 2006, 355: 2408-17. 10.1056\/NEJMoa062867","journal-title":"New England Journal of Medicine"},{"key":"454_CR3","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","volume":"6","author":"X Agirre","year":"2008","unstructured":"Agirre X, Jim\u00e9nez-Velasco A, San Jos\u00e9-En\u00e9riz E, Garate L, Bandr\u00e9s E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, P\u00e9rez-Roger I, Garc\u00eda-Foncillas J, Torres A, Heiniger A, Calasanz MJ, Fortes P, Rom\u00e1n-G\u00f3mez J, Pr\u00f3sper F: Hematopoietic tissue-specific hsa-miR-10a is down regulated in Chronic Myeloid Leukemia. Molecular Cancer Research. 2008, 6: 1830-40. 10.1158\/1541-7786.MCR-08-0167","journal-title":"Molecular Cancer Research"},{"key":"454_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nature03702","volume":"435","author":"J Lu","year":"2005","unstructured":"Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435: 834-8. 10.1038\/nature03702","journal-title":"Nature"},{"key":"454_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.leukres.2005.09.001","volume":"30","author":"SH Ramkissoon","year":"2006","unstructured":"Ramkissoon SH, Mainwaring LA, Ogasawara Y, Keyvanfar K, McCoy JP, Sloand EM, Kajigaya S, Young NS: Hematopoietic-specific microRNA expression in human cells. Leukemia Research. 2006, 30: 643-647. 10.1016\/j.leukres.2005.09.001","journal-title":"Leukemia Research"},{"key":"454_CR6","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","volume":"109","author":"L Venturini","year":"2007","unstructured":"Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M: Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007, 109: 4399-405. 10.1182\/blood-2006-09-045104","journal-title":"Blood"},{"key":"454_CR7","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1200\/JCO.2008.17.5554","volume":"26","author":"G Marcucci","year":"2008","unstructured":"Marcucci G, Maharry K, Radmacher MD, Mr\u00f3zek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 2008, 26: 5078-87. 10.1200\/JCO.2008.17.5554","journal-title":"Journal of Clinical Oncology"},{"key":"454_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/ijc.23501","volume":"123","author":"L Xia","year":"2008","unstructured":"Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. International Journal of Cancer. 2008, 123: 372-9. 10.1002\/ijc.23501. 10.1002\/ijc.23501","journal-title":"International Journal of Cancer"},{"key":"454_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.bcp.2008.06.007","volume":"76","author":"H Zhu","year":"2008","unstructured":"Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM: Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1\/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008, 76: 582-8. 10.1016\/j.bcp.2008.06.007","journal-title":"Biochem Pharmacol"},{"key":"454_CR10","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/sj.leu.2404310","volume":"20","author":"YJ Chung","year":"2006","unstructured":"Chung YJ, Kim TM, Kim DW, Namkoong H, Kim HK, Ha SA, Kim S, Shin SM, Kim JH, Lee YJ, Kang HM, Kim JW: Gene expression signatures associated with the resistance to imatinib. Leukemia. 2006, 20: 1542-50. 10.1038\/sj.leu.2404310","journal-title":"Leukemia"},{"key":"454_CR11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1124\/jpet.107.124461","volume":"322","author":"SM Lee","year":"2007","unstructured":"Lee SM, Bae JH, Kim MJ, Lee HS, Lee MK, Chung BS, Kim DW, Kang CD, Kim SH: Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther. 2007, 322: 1084-92. 10.1124\/jpet.107.124461","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-8-69.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:35:54Z","timestamp":1630452954000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-8-69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-8-69","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,1]]},"assertion":[{"value":"4 June 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"69"}}